Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenwei Hu

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Nature Communications|November 29, 2017
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progressionJuan Liu, Cen Zhang, Yuhan Zhao, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Cell Death & Disease|January 26, 2023
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumorsVrushank Bhatt, Taijin Lan, Wenping Wang, et al.
JCI Insight|July 21, 2020
Elevating EGFR-MAPK program by a nonconventional Cdc42 enhances intestinal epithelial survival and regenerationXiao Zhang, Sheila Bandyopadhyay, Leandro Pires Araujo, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 11, 2026
Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validationXiaohe Sun, Yan Fang, Xueying Yang, et al.
Cell Stem Cell|October 21, 2023
TGFB1 induces fetal reprogramming and enhances intestinal regenerationLei Chen, Xia Qiu, Abigail Dupre, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Nature Communications|November 29, 2017
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progressionJuan Liu, Cen Zhang, Yuhan Zhao, et al.
Cell|November 20, 2004
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansGareth L Bond, Wenwei Hu, Elisabeth E Bond, et al.
Cell Death & Disease|January 26, 2023
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumorsVrushank Bhatt, Taijin Lan, Wenping Wang, et al.
JCI Insight|July 21, 2020
Elevating EGFR-MAPK program by a nonconventional Cdc42 enhances intestinal epithelial survival and regenerationXiao Zhang, Sheila Bandyopadhyay, Leandro Pires Araujo, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|July 11, 2026
Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validationXiaohe Sun, Yan Fang, Xueying Yang, et al.
Cell Stem Cell|October 21, 2023
TGFB1 induces fetal reprogramming and enhances intestinal regenerationLei Chen, Xia Qiu, Abigail Dupre, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Pageof 16